Skip to main content

Table 3 Clinical cure at TOC visit by high-risk factor and pathogen type (CE population)

From: Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

  Number of patients
(ceftobiprole/ comparator)
Clinical cure at TOC
(%, ceftobiprole/ comparator)
Treatment difference (%)a 95% CIb
All patients (CAP) 231/238 86.6/87.4 −0.8 −6.9, 5.3
High-risk patients (CAP) 193/205 86.0/86.8 −0.8 −7.6, 5.9
 Any Gram-positive 29/40 89.7/90.0 −0.3 −14.8, 14.1
 Any Gram-negative 34/33 82.4/90.9 −8.6 −24.7, 7.6
 Any S. pneumoniae 26/33 92.3/90.9 1.4 −12.8, 15.6
 PORT ≥ III 126/117 86.5/86.3 0.2 −8.4, 8.8
 PORT ≥ IV 51/58 90.2/84.5 5.7 −6.7, 18.1
 Sepsis 123/135 84.6/86.7 −2.1 −10.7, 6.5
 Age ≥ 75 years 39/50 92.3/86.0 6.3 −6.4, 19.1
 COPD 51/59 86.3/86.4 −0.2 −13.0, 12.7
 ICU 25/26 72.0/61.5 10.5 −15.2, 36.1
All patients (HAP, excl. VAP) 198/185 77.8/76.2 1.6 −6.9, 10.0
High-risk patients (HAP, excl. VAP) 169/138 75.7/71.7 4.0 −5.9, 13.9
 Any Gram-positive 52/53 69.2/69.8 −2.5 −19.9, 15.0
 Any Gram-negative 65/60 67.7/73.3 −5.6 −21.6, 10.3
 Mixed/polymicrobial 29/35 62.1/68.6 −6.5 −29.9, 16.9
 Any S. aureus 35/38 68.6/71.1 −2.5 − 23.6, 18.6
 APACHE score ≥ 15 67/59 68.7/64.4 4.2 −12.3, 20.8
  >10 comorbidities 63/61 73.0/67.2 5.8 −10.3, 21.9
 Mechanical ventilation 38/37 55.3/40.5 14.7 −7.6, 37.1
 Age ≥ 75 years 59/54 72.9/77.8 −4.9 −20.8, 11.0
 COPD 55/39 83.6/76.9 6.7 −9.7, 23.2
 ICU 73/59 69.9/66.1 3.8 −12.3, 19.8
  1. aBetween treatment difference calculated as ceftobiprole minus ceftriaxone ± linezolid for patients with CAP, and ceftobiprole minus ceftazidime plus linezolid for patients with HAP (excluding VAP)
  2. bTwo-sided 95% CI is based on a normal approximation to the difference of the two proportions
  3. APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, CI confidence interval, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, MRSA methicillin-resistant Staphylococcus aureus, PORT Patient Outcome Research Team, TOC test-of-cure, VAP, ventilator-associated pneumonia